Johnson & Johnson notches 11% sales growth in Q3

Johnson & Johnson’s sales revenue climbed in the latest quarter, with $502 million in global Covid-19 vaccine sales buoying double-digit growth in the pharmaceutical division, according to financial results released Tuesday.

The New Brunswick, N.J., company said sales increased 11%, to $23.3 billion, in the third quarter, compared with the same period a year earlier. Earnings were $1.37 per share, up 3% year over year, or $2.60 per share if excluding special items.

Key to its growth were “robust above-market results” in pharmaceuticals, Chairman and CEO Alex Gorsky said. Sales in the division went up nearly 14% year over year, reaching $13 billion in the third quarter. Strong

→ Continue reading at Crain's New York Business

[ufc-fb-comments url=""]

Latest Articles

Related Articles